In this study, we obtained the target genes and target pathways of Fingolimod and IFN-β for MS treatment based on immune cell transcriptomic datasets of MS patients without treatment and immune cell transcriptomic datasets of MS patients before and after application of Fingolimod or IFN-β, and identified MS candidate drugs targeting hub target genes and target pathways. Here, IFNB1 is linked to myeloid sarcoma.